What Is Protegrin? Definition and What Research Reports

Definition

Protegrin is the name given to a small family of cationic, cysteine-rich antimicrobial peptides first identified in porcine (pig) leukocytes. The best-characterised member, protegrin-1 (commonly abbreviated PG-1), is roughly 16–18 amino acids long, carries a strong positive charge, and folds into a beta-hairpin stabilised by two intramolecular disulfide bridges. Protegrins are classified as cathelicidins — host-defence peptides that are stored as inactive precursors containing a conserved cathelin domain and released in an active form during innate immune responses. In the published literature the term "protegrin" is used both for the naturally occurring porcine peptides and for the many synthetic analogs and derivatives built on the PG-1 template.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the use of any substance. Protegrin and its analogs are described here strictly as subjects of laboratory research.

What Class of Molecule It Is

Protegrin sits inside a much larger group of molecules known as antimicrobial peptides (AMPs) or host-defence peptides. Structurally, protegrins fall into the beta-hairpin subclass — distinguishing them from the alpha-helical cathelicidin LL-37 found in humans and from the beta-sheet defensins. Key defining features described in the literature include:

• Origin: porcine cathelicidin, expressed in neutrophils and other immune cells.
• Charge: highly cationic, favouring interaction with negatively charged bacterial membranes.
• Structure: beta-hairpin constrained by two disulfide bonds, which contributes to stability.
• Nomenclature: PG-1 through PG-5 describe naturally described variants; IB-367 (iseganan) is a synthetic protegrin analog that has appeared in the antimicrobial literature.

How the Term Is Used in Peptide Research

Researchers use "protegrin" in three broad ways. First, as a specific molecule under study — usually PG-1 — in antimicrobial, cytotoxicity or immunology experiments. Second, as a scaffold or template: many papers describe engineered analogs in which residues are substituted to change charge, hydrophobicity or disulfide pattern. Third, as a comparator or reference peptide, placed alongside other host-defence peptides such as LL-37 to benchmark membrane activity. Because protegrin is a research peptide rather than an approved medicine, essentially all published work is in vitro (cell culture, isolated membranes, computational modelling) or in animal models.

What the Published Literature Reports

Antimicrobial and membrane activity

A 2024 review in Molecular Immunology summarised the antimicrobial and immunomodulatory activities attributed to porcine cathelicidin protegrin-1, describing its broad-spectrum action against bacteria and its additional roles in host immune signalling (PMID 39094445). A separate 2024 study combined in silico and in vitro assessment of novel antimicrobial peptides designed from the protegrin-1 sequence, reporting that computationally derived analogs retained antibacterial activity in laboratory testing (PMID 39288825). Activity has also been examined against fungi: researchers evaluated the protegrin analog IB-367 alone and in combination with conventional antifungal agents against dermatophytes in vitro, reporting measurable activity in that culture system (PMID 26058322).

Selectivity and analog design

A recurring theme in protegrin research is that the same membrane-disrupting property that makes the peptide antibacterial can also affect mammalian cells. A 2023 paper in Pharmaceutics described the design of protegrin-1 analogs intended to improve antibacterial selectivity — that is, to widen the gap between antimicrobial potency and activity against host cells (PMID 37631261). Earlier work reported that the immune-modulating activity of protegrin-1 analogs was structure-dependent, with changes to the peptide backbone altering the immunological readouts measured (PMID 26097747).

Cell-based and cancer-cell studies

Several studies have measured protegrin's effects on mammalian cell lines. Researchers evaluated the cytotoxic effect of protegrin PG-1 alongside cathelicidin LL-37, nerve growth factor, Streptococcus pyogenes strains and chemotherapy agents on the C6 glioma cell line in vitro (PMID 35056889). An earlier study expressed porcine protegrin-1 recombinantly in Pichia pastoris and reported anticancer activity of the resulting peptide in vitro (PMID 25667681). These are cell-culture observations; neither study described clinical outcomes in people.

Immune, gut and reproductive-tissue models

Beyond direct killing of microbes, protegrin has been studied as a signalling molecule. One study reported that protegrin-1 enhanced innate cellular defence via the insulin-like growth factor 1 receptor pathway (PMID 30324092). In a murine model of dextran sodium sulfate-induced colitis, researchers reported protective effects of protegrin on the inflamed intestine (PMID 30873029). In porcine ovarian granulosa cells, one study reported that protegrin-1 inhibited apoptosis triggered by hydrogen peroxide-induced oxidative stress, implicating the PERK/eIF2α/CHOP signalling pathway in vitro (PMID 34864562), while transcriptome profiling in the same cell type described transcriptional regulation by protegrin-1 of genes linked to immune defence and development (PMID 37741593).

An unexpected direction: amyloid

Protegrin's beta-hairpin structure has also attracted interest outside infection biology. A 2023 report in ACS Chemical Neuroscience described repurposing antimicrobial protegrin-1 as a dual-function amyloid inhibitor acting through cross-seeding (PMID 37589476). This illustrates how the protegrin scaffold is used as a starting point in fields well beyond its original antimicrobial description.

Quick Reference

Cytotoxicity and Tolerability: What Studies Report

Published protegrin work repeatedly returns to the question of host-cell toxicity. Because protegrin acts on lipid membranes, researchers have measured its effects on mammalian cells directly: one in vitro evaluation assessed the cytotoxic effect of protegrin PG-1 on the C6 glioma cell line alongside other agents (PMID 35056889), and analog-design work was explicitly framed around improving antibacterial selectivity relative to the parent peptide (PMID 37631261). The 2024 review of protegrin-1 discussed both its antimicrobial and immunomodulatory activities within that same host-interaction context (PMID 39094445). No human safety or tolerability profile is established in the verified literature summarised here.

Limitations of the Evidence

• The overwhelming majority of protegrin findings come from in vitro systems, where peptide concentration, salt content and serum proteins strongly influence results.
• Animal work described above used rodent colitis and porcine cell models (PMID 30873029, PMID 34864562); such models do not establish human outcomes.
• "Protegrin" in a paper title may refer to the natural peptide or to an engineered analog with different properties, so findings are not automatically transferable between them.

Protegrin is a research-stage peptide. Nothing on this page describes an approved therapy, and nothing here should be read as direction about using any compound.

References

• Antimicrobial and immunomodulatory activities of porcine cathelicidin Protegrin-1 (Molecular Immunology, 2024)
• Novel antimicrobial peptides based on Protegrin-1: In silico and in vitro assessments (Microbial Pathogenesis, 2024)
• Design of Protegrin-1 Analogs with Improved Antibacterial Selectivity (Pharmaceutics, 2023)
• Repurposing Antimicrobial Protegrin-1 as a Dual-Function Amyloid Inhibitor via Cross-seeding (ACS Chemical Neuroscience, 2023)
• In Vitro Evaluation of the Cytotoxic Effect of Streptococcus pyogenes Strains, Protegrin PG-1, Cathelicidin LL-37, Nerve Growth Factor and Chemotherapy on the C6 Glioma Cell Line (Molecules, 2022)
• Expression of porcine protegrin-1 in Pichia pastoris and its anticancer activity in vitro (Experimental and Therapeutic Medicine, 2015)
• In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes (Mycoses, 2014)
• Protective Effects of Protegrin in Dextran Sodium Sulfate-Induced Murine Colitis (Frontiers in Pharmacology, 2019)
• Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs (Antibiotics, 2014)
• Transcriptome profiling reveals transcriptional regulation of Protegrin-1 on immune defense and development in porcine granulosa cells (Gene, 2024)
• Protegrin 1 Enhances Innate Cellular Defense via the Insulin-Like Growth Factor 1 Receptor Pathway (Frontiers in Cellular and Infection Microbiology, 2018)
• Protegrin-1 inhibits porcine ovarian granulosa cell apoptosis from H2O2-induced oxidative stress via the PERK/eIF2α/CHOP signaling pathway in vitro (Theriogenology, 2022)